Literature DB >> 14517305

The COOH-terminal domain of wild-type Cot regulates its stability and kinase specific activity.

Maria Luisa Gándara1, Pilar López, Raquel Hernando, José G Castaño, Susana Alemany.   

Abstract

Cot, initially identified as an oncogene in a truncated form, is a mitogen-activated protein kinase kinase kinase implicated in cellular activation and proliferation. Here, we show that this truncation of Cot results in a 10-fold increase in its overall kinase activity through two different mechanisms. Truncated Cot protein exhibits a lower turnover rate (half-life, 95 min) than wild-type Cot (half-life, 35 min). The degradation of wild-type and truncated Cot can be specifically inhibited by proteasome inhibitors in situ. The 20S proteasome also degrades wild-type Cot more efficiently than the truncated protein. Furthermore, the amino acid 435 to 457 region within the wild-type Cot COOH-terminal domain confers instability when transferred to the yellow fluorescent protein and targets this fusion protein to degradation via the proteasome. On the other hand, the kinase specific activity of wild-type Cot is 3.8-fold lower than that of truncated Cot, and it appears that the last 43 amino acids of the wild-type Cot COOH-terminal domain are those responsible for this inhibition of kinase activity. In conclusion, these data demonstrate that the oncogenic activity of truncated Cot is the result of its prolonged half-life and its higher kinase specific activity with respect to wild-type Cot.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14517305      PMCID: PMC230324          DOI: 10.1128/MCB.23.20.7377-7390.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  69 in total

1.  Tpl-2 induces IL-2 expression in T-cell lines by triggering multiple signaling pathways that activate NFAT and NF-kappaB.

Authors:  C Tsatsanis; C Patriotis; P N Tsichlis
Journal:  Oncogene       Date:  1998-11-19       Impact factor: 9.867

Review 2.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

3.  Cot kinase activates tumor necrosis factor-alpha gene expression in a cyclosporin A-resistant manner.

Authors:  A Ballester; A Velasco; R Tobeña; S Alemany
Journal:  J Biol Chem       Date:  1998-06-05       Impact factor: 5.157

4.  Dissection of c-MOS degron.

Authors:  Jun Sheng; Akiko Kumagai; William G Dunphy; Alexander Varshavsky
Journal:  EMBO J       Date:  2002-11-15       Impact factor: 11.598

5.  The oncogenic protein kinase Tpl-2/Cot contributes to Epstein-Barr virus-encoded latent infection membrane protein 1-induced NF-kappaB signaling downstream of TRAF2.

Authors:  Aristides G Eliopoulos; Clare Davies; Sarah S M Blake; Paul Murray; Sohrab Najafipour; Philip N Tsichlis; Lawrence S Young
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  The Tpl-2 protooncoprotein activates the nuclear factor of activated T cells and induces interleukin 2 expression in T cell lines.

Authors:  C Tsatsanis; C Patriotis; S E Bear; P N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

7.  Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals.

Authors:  Aristides G Eliopoulos; Calin D Dumitru; Chun-Chi Wang; Jeonghee Cho; Philip N Tsichlis
Journal:  EMBO J       Date:  2002-09-16       Impact factor: 11.598

8.  Akt-dependent phosphorylation specifically regulates Cot induction of NF-kappa B-dependent transcription.

Authors:  Lawrence P Kane; Marianne N Mollenauer; Zheng Xu; Christoph W Turck; Arthur Weiss
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

9.  Mouse c-mos oncogene activation is prevented by upstream sequences.

Authors:  T G Wood; M L McGeady; B M Baroudy; D G Blair; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

10.  TPL-2 kinase regulates the proteolysis of the NF-kappaB-inhibitory protein NF-kappaB1 p105.

Authors:  M P Belich; A Salmerón; L H Johnston; S C Ley
Journal:  Nature       Date:  1999-01-28       Impact factor: 49.962

View more
  13 in total

1.  Phosphorylation at Thr-290 regulates Tpl2 binding to NF-kappaB1/p105 and Tpl2 activation and degradation by lipopolysaccharide.

Authors:  Jeonghee Cho; Philip N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-07       Impact factor: 11.205

2.  Cytomegalovirus promoter up-regulation is the major cause of increased protein levels of unstable reporter proteins after treatment of living cells with proteasome inhibitors.

Authors:  Beatriz Alvarez-Castelao; Idoia Martín-Guerrero; Africa García-Orad; José G Castaño
Journal:  J Biol Chem       Date:  2009-08-13       Impact factor: 5.157

3.  Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations.

Authors:  Brian D Lehmann; Timothy M Shaver; Douglas B Johnson; Zhu Li; Paula I Gonzalez-Ericsson; Violeta Sánchez; Yu Shyr; Melinda E Sanders; Jennifer A Pietenpol
Journal:  Mol Cancer Res       Date:  2019-06-11       Impact factor: 5.852

4.  Cot/tpl2 (MAP3K8) mediates myeloperoxidase activity and hypernociception following peripheral inflammation.

Authors:  Irene Soria-Castro; Agnieszka Krzyzanowska; Marta López Pelaéz; Javier Regadera; Gema Ferrer; Lluis Montoliu; Rosario Rodríguez-Ramos; Margarita Fernández; Susana Alemany
Journal:  J Biol Chem       Date:  2010-08-24       Impact factor: 5.157

5.  Genome remodelling in a basal-like breast cancer metastasis and xenograft.

Authors:  Li Ding; Matthew J Ellis; Shunqiang Li; David E Larson; Ken Chen; John W Wallis; Christopher C Harris; Michael D McLellan; Robert S Fulton; Lucinda L Fulton; Rachel M Abbott; Jeremy Hoog; David J Dooling; Daniel C Koboldt; Heather Schmidt; Joelle Kalicki; Qunyuan Zhang; Lei Chen; Ling Lin; Michael C Wendl; Joshua F McMichael; Vincent J Magrini; Lisa Cook; Sean D McGrath; Tammi L Vickery; Elizabeth Appelbaum; Katherine Deschryver; Sherri Davies; Therese Guintoli; Li Lin; Robert Crowder; Yu Tao; Jacqueline E Snider; Scott M Smith; Adam F Dukes; Gabriel E Sanderson; Craig S Pohl; Kim D Delehaunty; Catrina C Fronick; Kimberley A Pape; Jerry S Reed; Jody S Robinson; Jennifer S Hodges; William Schierding; Nathan D Dees; Dong Shen; Devin P Locke; Madeline E Wiechert; James M Eldred; Josh B Peck; Benjamin J Oberkfell; Justin T Lolofie; Feiyu Du; Amy E Hawkins; Michelle D O'Laughlin; Kelly E Bernard; Mark Cunningham; Glendoria Elliott; Mark D Mason; Dominic M Thompson; Jennifer L Ivanovich; Paul J Goodfellow; Charles M Perou; George M Weinstock; Rebecca Aft; Mark Watson; Timothy J Ley; Richard K Wilson; Elaine R Mardis
Journal:  Nature       Date:  2010-04-15       Impact factor: 49.962

6.  Phosphorylation of TPL-2 on serine 400 is essential for lipopolysaccharide activation of extracellular signal-regulated kinase in macrophages.

Authors:  M J Robinson; S Beinke; A Kouroumalis; P N Tsichlis; S C Ley
Journal:  Mol Cell Biol       Date:  2007-08-20       Impact factor: 4.272

7.  Cot/tpl2 participates in the activation of macrophages by adiponectin.

Authors:  Carlos Sanz-Garcia; Laura E Nagy; Miguel A Lasunción; Margarita Fernandez; Susana Alemany
Journal:  J Leukoc Biol       Date:  2014-02-14       Impact factor: 4.962

8.  Sterile inflammation in acetaminophen-induced liver injury is mediated by Cot/tpl2.

Authors:  Carlos Sanz-Garcia; Gemma Ferrer-Mayorga; Águeda González-Rodríguez; Angela M Valverde; Antonio Martín-Duce; Juan P Velasco-Martín; Javier Regadera; Margarita Fernández; Susana Alemany
Journal:  J Biol Chem       Date:  2013-04-09       Impact factor: 5.157

Review 9.  Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase.

Authors:  Thorsten Gantke; Srividya Sriskantharajah; Steven C Ley
Journal:  Cell Res       Date:  2010-12-07       Impact factor: 25.617

10.  IκB kinase-induced interaction of TPL-2 kinase with 14-3-3 is essential for Toll-like receptor activation of ERK-1 and -2 MAP kinases.

Authors:  Abduelhakem Ben-Addi; Agnes Mambole-Dema; Christine Brender; Stephen R Martin; Julia Janzen; Sven Kjaer; Stephen J Smerdon; Steven C Ley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.